Global Semaglutide Intermediate P29 Market Strategic Research Report

Scope of the Report

The global Semaglutide Intermediate P29 market size is predicted to grow from US$ 128 million in 2025 to US$ 1,004 million in 2032; it is expected to grow at a CAGR of 34.6% from 2026 to 2032.

Semaglutide Intermediate P29 is a key intermediate compound in the synthesis process of Semaglutide, playing an important role. Semaglutide is a GLP-1 receptor agonist widely used for the treatment of type 2 diabetes and obesity, effectively controlling blood sugar and weight by regulating insulin secretion, suppressing appetite, and enhancing satiety. P29 undergoes several chemical reactions in the production of Semaglutide, including peptide coupling, protection/deprotection reactions, and selective functional group transformations, ultimately converting into the active drug component. With the increasing prevalence of type 2 diabetes and obesity, as well as the widespread recognition of Semaglutide’s efficacy in treating these two conditions, the market demand for Semaglutide and its intermediates continues to grow. The global demand for GLP-1 receptor agonists is increasing, driving the need for Semaglutide and its production materials, and this trend is expected to continue promoting the development of the Semaglutide industry chain.

The surge in global demand for GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Rybelsus) is directly driving increased need for semaglutide APIs and their upstream intermediates like P29 peptide. As semaglutide becomes a cornerstone therapy not only for diabetes but also for obesity, cardiovascular prevention, and potentially neurodegenerative diseases, the demand for high-purity intermediates is accelerating globally.

With oral semaglutide (Rybelsus) gaining popularity, formulation complexity has increased. This boosts the importance of highly consistent, bioactive intermediate peptides like P29. Manufacturers that can provide GMP-compliant, injectable-grade and oral-grade P29 peptides will have a competitive advantage.

China and India are emerging as key suppliers of semaglutide intermediates, especially as they scale up CDMO capabilities (Contract Development and Manufacturing Organizations). More companies are investing in fermentation-based expression systems and solid-phase synthesis automation to improve cost-efficiency and scale.

The expiration clock on Ozempic and Wegovy is ticking, prompting generic and biosimilar players (notably in India) to explore backward integration. This places P29 at the center of licensing, formulation, and IP circumvention strategies.

This report presents a comprehensive overview of the global Semaglutide Intermediate P29 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• ≥99%
• Others

Segment by Application

• Oral Preparations
• Injections

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Semaglutide Intermediate P29 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Oral Preparations, Injections evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact